Scott L. Burrows, Chief Financial Officer at Spyre Therapeutics, Inc. (SYRE), sold 37,062 shares at $28.17 ($1.0M) on 2024-09-03, disclosed to the SEC on 2024-09-05.
Open-market sale of $1.0M SYRE by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $28.17 | 18,531 | $522K | 50.0% |
| 2 | $28.17 | 18,531 | $522K | 50.0% |
| Total | $28.17 avg | 37,062 | $1.0M | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $717K | — | Filing → |
| SYRE | SELL | 2026-07-02 | $658K | — | Filing → |
| SYRE | SELL | 2026-06-26 | $1.3M | — | Filing → |